Top Players and Competitive Dynamics in the Psoriasis Biosimilars Market

The psoriasis biosimilars market is set for significant expansion in the coming years as advancements in treatment options and broader access to affordable drugs gain momentum. The market is evolving rapidly, driven by new product launches and growing healthcare infrastructure. Let's explore the current market size, key players, emerging trends, and segmentation to understand the future outlook of this important healthcare sector.

Forecasted Growth Trajectory of the Psoriasis Biosimilars Market
The psoriasis biosimilars market is projected to experience swift growth, reaching a valuation of $13.79 billion by 2030. This corresponds to a compound annual growth rate (CAGR) of 11.0%. The anticipated expansion is largely due to the introduction of new biosimilars for drugs like infliximab, etanercept, and adalimumab. Additionally, the expansion of hospital and online pharmacy networks, rising healthcare spending on dermatology, increased uptake of patient assistance programs, and an upsurge in clinical trials for novel biosimilars are all key contributors. Notable trends during the forecast period include greater adoption of cost-effective biosimilars, enhanced focus on patient affordability and access, growth in both subcutaneous and intravenous treatment options, expansion of hospital and retail pharmacy channels, and the development of targeted therapies tailored for various psoriasis types.

Download a free sample of the psoriasis biosimilars market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27399&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Factors Boosting Demand for Psoriasis Biosimilars
One of the main growth drivers is the increasing availability of affordable biosimilars, which makes effective psoriasis treatments accessible to a wider patient population. This affordability factor helps reduce the overall healthcare burden by offering alternatives to expensive biologic drugs.
Moreover, the expansion of healthcare infrastructure, particularly in hospital and retail pharmacy networks as well as online platforms, is facilitating easier distribution and availability of these biosimilars. This expanded access supports higher adoption rates and better patient outcomes.

Leading Organizations in the Psoriasis Biosimilars Industry
The psoriasis biosimilars market is dominated by several prominent pharmaceutical companies, including Pfizer Inc., Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Samsung Bioepis Co. Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., and Alvotech hf.
In a notable collaboration in September 2023, Sandoz Group AG joined forces with Samsung Bioepis to commercialize the biosimilar SB17 (ustekinumab). This partnership aims to bring this biosimilar for conditions like plaque psoriasis to markets in Europe and North America, enhancing patient access to affordable and high-quality immunology treatments. Samsung Bioepis, a South Korean biopharmaceutical company, specializes in developing biosimilars including those targeting plaque psoriasis.

View the full psoriasis biosimilars market report:
https://www.thebusinessresearchcompany.com/report/psoriasis-biosimilars-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends Shaping the Future of Psoriasis Biosimilars
Pharmaceutical companies in this sector are concentrating on innovation by introducing biosimilars specifically for plaque psoriasis to improve treatment availability while lowering healthcare costs. These biosimilars serve as cost-effective and highly similar alternatives to existing biologic therapies for the chronic autoimmune condition marked by red and scaly skin patches.
For example, in May 2025, Sandoz Group AG launched Pyzchiva, the first commercially available ustekinumab biosimilar autoinjector. Approved for adults and pediatric patients with plaque psoriasis and certain related conditions, this device is designed to enhance patient adherence. It offers features such as precise automatic dosing, reduced injection discomfort, a compact form factor, and flexible storage options to facilitate easier self-administration.

Detailed Breakdown of the Psoriasis Biosimilars Market
This report segments the psoriasis biosimilars market as follows:
1) Drug Class: TNF-Alpha Inhibitors, infliximab, etanercept, adalimumab, and other biosimilars
2) Disease Type: Plaque psoriasis, guttate psoriasis, inverse psoriasis, and pustular psoriasis
3) Route of Administration: Subcutaneous, intravenous, oral, and topical
4) Distribution Channel: Hospital pharmacies, retail pharmacies, and online pharmacies

Further subcategories include:
- TNF-Alpha Inhibitors: monoclonal antibody biosimilars and fusion protein biosimilars
- Infliximab: Remicade biosimilars and CT-P13 biosimilars
- Etanercept: Enbrel biosimilars and SB4 biosimilars
- Adalimumab: Humira biosimilars and ABP 501 biosimilars
- Other Biosimilars: ustekinumab biosimilars and secukinumab biosimilars

This comprehensive segmentation highlights the diversity of treatment options available and the multiple routes through which psoriasis biosimilars are reaching patients worldwide.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.